Related Experiment Video
Updated: Mar 7, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
Wei-Gang Qiu1, Alla Polotskaia2, Gu Xiao2
1The Department of Biological Sciences Hunter College, City University of New York, Hunter College-Weill Cornell Belfer Research Building, 413 East 69th, New York, NY 10065, USA; The Graduate Center PhD Program in Biology, City University of New York, New York, NY 10016, USA; Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
Abstract:
Over 80% of triple negative breast cancers express mutant p53. Mutant p53 often gains oncogenic function suggesting that triple negative breast cancers may be driven by p53 protein type. To determine the chromatin targets of this gain-of-function mutant p53 we used inducible knockdown of endogenous gain-of-function mtp53 in MDA-MB-468 cells in conjunction with stable isotope labeling with amino acids in cell culture and subcellular fractionation. We sequenced over 70,000 total peptides for each corresponding reciprocal data set and were able to identify 3010 unique cytoplasmic fraction proteins and 3403 unique chromatin fraction proteins. The present proteomics experiment corroborated our previous experiment-based results that poly ADP-ribose polymerase has a positive association with mutant p53 on the chromatin. Here, for the first time we report that the heterohexomeric minichromosome maintenance complex that participates in DNA replication initiation ranked as a high mutant p53-chromatin associated pathway. Enrichment analysis identified the minichromosome maintenance members 2-7. To validate this mutant p53- poly ADP-ribose polymerase-minichromosome maintenance functional axis, we experimentally depleted R273H mutant p53 and found a large reduction of the amount of minichromosome maintenance complex proteins on the chromatin. Furthermore a mutant p53-minichromosome maintenance 2 direct interaction was detected. Overexpressed mutant p53, but not wild type p53, showed a protein-protein interaction with minichromosome maintenance 2 and minichromosome maintenance 4. To target the mutant p53- poly ADP-ribose polymerase-minichromosome maintenance axis we treated cells with the poly ADP-ribose polymerase inhibitor talazoparib and the alkylating agent temozolomide and detected synergistic activation of apoptosis only in the presence of mutant p53. Furthermore when minichromosome maintenance 2-7 activity was inhibited the synergistic activation of apoptosis was blocked. This mutant p53- poly ADP-ribose polymerase -minichromosome maintenance axis may be useful for theranostics.
Insights
Triple-negative breast cancers often harbor mutant p53, driving cancer growth. Researchers identified a new mutant p53-chromatin pathway involving the minichromosome maintenance complex, offering potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Over 80% of triple-negative breast cancers (TNBC) express mutant p53, which can gain oncogenic functions.
- This suggests that mutant p53 protein type may drive TNBC progression.
Purpose of the Study:
- To identify the specific chromatin targets of gain-of-function mutant p53 in TNBC.
- To investigate the functional axis involving mutant p53, poly (ADP-ribose) polymerase, and the minichromosome maintenance complex.
Main Methods:
- Utilized inducible knockdown of mutant p53 in MDA-MB-468 cells.
- Employed stable isotope labeling with amino acids in cell culture (SILAC) and subcellular fractionation coupled with mass spectrometry.
- Performed protein-protein interaction studies and targeted inhibition of key pathway components.
Main Results:
- Identified 3403 unique chromatin-associated proteins, confirming a positive association between poly (ADP-ribose) polymerase and mutant p53 on chromatin.
- Reported the minichromosome maintenance (MCM) complex (MCM2-7) as a novel high-affinity mutant p53-chromatin target.
- Demonstrated that depleting mutant p53 reduced MCM complex association with chromatin and that mutant p53 directly interacts with MCM2 and MCM4.
- Showed that combined inhibition of poly (ADP-ribose) polymerase and MCM complex activity synergistically activated apoptosis in mutant p53-expressing TNBC cells.
Conclusions:
- A functional axis involving mutant p53, poly (ADP-ribose) polymerase, and the MCM complex drives TNBC.
- Targeting this axis, particularly with poly (ADP-ribose) polymerase inhibitors, shows promise for TNBC theranostics.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

